Altria Group News Monitoring

Get by Email • RSS

Published on Jun 1, 2025

Dividend Powerhouse Altria Group (MO) Lures Value Investors With 7% Yield

If you’re seeking a dependable dividend stock with a generous yield, Altria Group (MO)—the U.S. parent company of Marlboro—is hard to ignore. Offering a nearly 7% dividend yield and boasting over 50 years of uninterrupted dividend growth, Altria stands out …

Source: Yahoo Finance - Center-left
Published on Jun 1, 2025

3 Must-Buy Dividend ETFs Under $50 for 2025

Key Points These three dividend ETFs can generate steady passive income at low-cost. Each of these ETFs offer elite stocks with ultimate portfolio diversification. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a …

Source: 24/7 Wall St. - Pending
Published on May 31, 2025

Can I Rely on Dividends for Life After Quitting My Job?

As always, The Motley Fool cannot and does not provide personalized investing or financial advice. This information is for informational and educational purposes only and is not a substitute for professional financial advice. Always seek the guidance of a …

Source: The Motley Fool USA - Neutral
Published on May 30, 2025

Better High-Yield Dividend Stock: Altria or British American Tobacco?

These stocks look like twins at first glance, but a deeper look reveals key differences. Sin stocks, such as tobacco companies, aren't for everyone, but they make excellent dividend stocks due to their entrenched and resilient business models and huge …

Source: The Motley Fool USA - Neutral

29 days 22:28:22

Featured Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 11:00 GMT

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory ...

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-...

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 2, 2025 - 11:00 GMT

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 10:30 GMT

Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company ...

LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the sale of its minority equity interest in a privately held pharmaceutical …

Distribution channels:

Published on June 2, 2025 - 05:00 GMT

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short ...

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 05:00 GMT

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques ...

Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé, en croissance rapide, pour la …

Distribution channels:
Published on June 1, 2025 - 23:30 GMT

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“ …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Got news to share? Submit it now.

Load more pharmaceuticals news or search news using your own keywords. There are 818,232,072 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country

Pharmaceutical Industry News by U.S. State

Pharmaceutical Industry News Topics

Online News Publications

World News Report

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter

Create RSS Feed

NewsPlugin for WordPress

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire

Events

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 05/18/2025

World Media Directory

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 11:00 GMT

Functional Pathways Selected as Contract Therapy Partner for Covenant Living Communities

Covenant Living has selected Functional Pathways to serve as its exclusive contract therapy partner for its 20 communities across 11 states. KNOXVILLE, TN, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Functional Pathways, one of the nation’ …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 09:30 GMT

Dr. Ushma Kakkad Earns Certification in Conscious Sedation with Nitrous Oxide from IDA

Certification empowers Dr. Kakkad to offer anxiety-free dental care using nitrous oxide for kids and adults at Summirow Dental Hospital. SURAT, GUJARAT, INDIA, June 2, 2025 /⁨EINPresswire.com⁩/ -- Introduction We’re proud to share some exciting …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 08:08 GMT

Bracane Company Earns Ecovadis Silver Medal for Sustainability Excellence

Ranked Among Top 15% of Companies Globally, Underscoring Bracane’s Commitment to Environmental Stewardship, Social Responsibility, and Ethical Governance PLANO, TX, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Bracane Company, Inc., a …

Distribution channels: Education, Energy Industry ...
Published on June 2, 2025 - 07:49 GMT

MOIN Launches Cross-Border Remittance Service via Toss App, Enhancing Accessibility for 28 Million Users

MOIN, a leading fintech company specializing in cross-border remittance solutions, has launched its cross-border money transfer service on Toss SEOUL, EUNPYEONG, SOUTH KOREA, June 2, 2025 /⁨EINPresswire.com⁩/ -- MOIN, a leading fintech company …

Distribution channels: Amusement, Gaming & Casino, Automotive Industry ...
Published on June 2, 2025 - 06:51 GMT

Narconon Arrowhead Hosts Celebration for Graduate's 25 Years of Sobriety

CANADIAN, OK, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- The Narconon Arrowhead Drug and Alcohol Rehabilitation Program recently hosted a special celebration as Bobby Newman, a program graduate, marked 25 years of sobriety. Newman, who …

Distribution channels: Culture, Society & Lifestyle, Education ...
Published on June 1, 2025 - 23:16 GMT

Luis M. Gallardo Launches the Meta Pets Method, A Playful Path to Transformation for Therapists, Coaches, and Educators

A Card-Based System for Self-Inquiry, Healing, and Awakening in Education, Coaching, and Therapy. MIAMI, FL, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- Author, hypnotherapist, and global well-being advocate Luis Miguel Gallardo announces …

Distribution channels: Book Publishing Industry, Business & Economy ...
Published on June 2, 2025 - 11:05 GMT

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:05 GMT

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful ...

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next- …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory ...

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a ...

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder …

Distribution channels: Business & Economy, Companies ...
Published on June 1, 2025 - 23:00 GMT

Impelsys Strengthens AI Transformation Strategy with AlgoShack Partnership

NEW YORK, NY, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Impelsys, a global leader in technology solutions, is pleased to announce its strategic partnership with AlgoShack, a company that offers algoQA—a unified platform for end-to-end …

Distribution channels: Book Publishing Industry, Education ...
Published on June 2, 2025 - 11:00 GMT

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically ...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
Published on June 2, 2025 - 11:00 GMT

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-...

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare ...

LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- InStride, a leading provider of strategic education and skilling solutions, has facilitated a unique partnership between Arizona State University’s College of Health Solutions and Labcorp, a global leader of …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 ...

Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide …

Distribution channels: Healthcare & Pharmaceuticals Industry ...